Lineage Cell Therapeutics (LCTX)
Develops off-the-shelf cell-replacement therapies for retinal, spinal-cord, hearing and corneal disease.
$0.9701
vs last close−0.07 (−6.72%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 43 days
EPS estimate
−$0.03
Revenue estimate
$1.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.01−$0.02−$0.01−$0.13$0.00−$0.03−$0.03Pending
Estimate−$0.04−$0.02−$0.02−$0.02−$0.04−$0.02−$0.03−$0.03
Surprise+75.0%0.0%+50.0%−550.0%+109.2%−50.0%−5.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.9M$1.5M$2.8M$3.7M$6.6M$1.7M$1.1MPending
Estimate$1.6M$1.7M$1.5M$2.0M$2.0M$3.6M$1.8M$1.3M
Surprise+78.9%−12.9%+88.6%+87.8%+236.8%−52.1%−42.0%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.04 | — | — |
| Sep 2028 | −$0.03 | — | — |
| Jun 2028 | −$0.03 | — | — |
| Mar 2028 | −$0.03 | — | — |
| Dec 2027 | −$0.03 | — | — |
| Sep 2027 | −$0.03 | — | — |
| Jun 2027 | −$0.03 | — | — |
| Mar 2027 | −$0.03 | — | — |
| Dec 2026 | −$0.01 | — | — |
| Nov 2026 | −$0.03 | — | — |
| Aug 2026 | −$0.03 | −$0.03 | −5.9% |
| May 2026 | −$0.02 | −$0.03 | −50.0% |
| Mar 2026 | −$0.04 | $0.00 | +109.2% |
| Nov 2025 | −$0.02 | −$0.13 | −550.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.04 | — | — | $1.9M | — | — | — |
| Sep 2028 | −$0.03 | — | — | $1.9M | — | — | — |
| Jun 2028 | −$0.03 | — | — | $1.9M | — | — | — |
| Mar 2028 | −$0.03 | — | — | $1.9M | — | — | — |
| Dec 2027 | −$0.03 | — | — | $1.5M | — | — | — |
| Sep 2027 | −$0.03 | — | — | $1.5M | — | — | — |
| Jun 2027 | −$0.03 | — | — | $1.5M | — | — | — |
| Mar 2027 | −$0.03 | — | — | $1.5M | — | — | — |
| Dec 2026 | −$0.01 | — | — | $10.6M | — | — | — |
| Nov 5, 2026 | −$0.03 | — | — | $1.3M | — | — | — |
| Aug 6, 2026 | −$0.03 | −$0.03 | −5.9% | $1.8M | $1.1M | −42.0% | −2.7% |
| May 12, 2026 | −$0.02 | −$0.03 | −50.0% | $3.6M | $1.7M | −52.1% | −3.8% |
| Mar 5, 2026 | −$0.04 | $0.00 | +109.2% | $2.0M | $6.6M | +236.8% | +0.5% |
| Nov 6, 2025 | −$0.02 | −$0.13 | −550.0% | $2.0M | $3.7M | +87.8% | +1.7% |
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 10, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 7, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 9, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 10, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 11, 2021 | |||||||
| Nov 4, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 14, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 15, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 2, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 16, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 10, 2016 | |||||||
| Mar 15, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 |